drugset / Trial / NCT01023724

A Comparison of Post Phacoemulsification Aqueous Flare in Patients Using Ketorolac 0.45% 2 Times Daily (BID) and Bromfenac 0.09% 2 Times Daily (BID)

NCT01023724

Phase 4 Completed 50 enrolled Bucci Laser Vision Institute Allergan · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

Approximately 50 patients undergoing cataract surgery will be randomized in an even allocation (1:1) into two treatment groups, either ketorolac 0.45% BID or bromfenac 0.09% BID. Patients will be instructed to begin dosing study medication in the operative eye the day before surgery and continue dosing until day 14. KOWA flare measurements will be performed at postoperative day one and postoperative day 14. The amount of anterior chamber inflammation (flare) will be objectively measured.

Timeline

Start
2009-12
Primary completion
2010-01
Completion
2010-02

Drugs

EvaluationDrugModalityDoseRoute
Comparator Bromfenac Other / unclassified 0.09 % Topical
Comparator Ketorolac Tromethamine Small molecule 0.45 % Topical

Indications